Elanco's aqua business includes products across both warm-water and cold-water species, generating an estimated $175 million in revenue and approximately $92 million in adjusted EBITDA, excluding the allocation of corporate costs, based on 2023 preliminary results. The divestiture includes current marketed brands, aqua R&D projects, the transfer of manufacturing sites in Prince Edward Island, Canada and Dong Nai, Vietnam and approximately 280 commercial and manufacturing employees.
Elanco Animal Health Has Agreed To Sell Its Aqua Business To Merck's Animal Health For Approximately $1.3 Billion In Cash, Which Represents Approximately 7.4x The Estimated 2023 Revenue Of The Elanco Aqua Business
Company Profile